Salvage therapy in patients with glioblastoma: is there any benefit? (Q47326771)

14 January 2018

title

Salvage therapy in patients with glioblastoma: is there any benefit? (English)

1 reference

14 January 2018

1 reference

12

Gerhard Schuierer

1 reference

14 January 2018

Ulrich Bogdahn

17

object named as

Ulrich Bogdahn

1 reference

14 January 2018

Peter Hau

1

object named as

Peter Hau

1 reference

14 January 2018

Alexander Brawanski

16

object named as

Alexander Brawanski

1 reference

14 January 2018

author name string

Ulrike Baumgart

2

1 reference

14 January 2018

Katharina Pfeifer

3

1 reference

14 January 2018

Anne Bock

4

1 reference

14 January 2018

Tanya Jauch

5

1 reference

14 January 2018

Jörg Dietrich

6

1 reference

14 January 2018

Klaus Fabel

7

1 reference

14 January 2018

Oliver Grauer

8

1 reference

14 January 2018

Caecilia Wismeth

9

1 reference

14 January 2018

Monika Klinkhammer-Schalke

10

1 reference

14 January 2018

Michael Allgäuer

11

1 reference

14 January 2018

Horst Koch

13

1 reference

14 January 2018

Juergen Schlaier

14

1 reference

14 January 2018

Winfried Ulrich

15

1 reference

14 January 2018

Andreas Steinbrecher

18

1 reference

14 January 2018

language of work or name

English

0 references

publication date

1 December 2003

1 reference

14 January 2018

number of pages

9

1 reference

based on heuristic

inferred from page(s)

published in

Cancer

1 reference

14 January 2018

volume

98

1 reference

14 January 2018

issue

12

1 reference

14 January 2018

page(s)

2678-2686

1 reference

14 January 2018

Survival rates in patients with primary malignant brain tumors stratified by patient age and tumor histological type: an analysis based on Surveillance, Epidemiology, and End Results (SEER) data, 1973-1991.

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11845

Glioblastoma multiforme and anaplastic astrocytoma. Pathologic criteria and prognostic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11845

The prognostic importance of tumor size in malignant gliomas: a computed tomographic scan study by the Brain Tumor Cooperative Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11845

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11845

Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11845

The role of chemotherapy in recurrent malignant gliomas: an overview

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11845

Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11845

Neuro-Oncology Working Group 01 trial of nimustine plus teniposide versus nimustine plus cytarabine chemotherapy in addition to involved-field radiotherapy in the first-line treatment of malignant glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11845

Randomized trial of procarbazine, lomustine, and vincristine in the adjuvant treatment of high-grade astrocytoma: a Medical Research Council trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11845

Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11845

A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11845

Long-term stabilization in patients with malignant glioma after treatment with liposomal doxorubicin

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11845

Response criteria for phase II studies of supratentorial malignant glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11845

Extent of resection in malignant gliomas: a critical summary.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11845

Nonparametric Estimation from Incomplete Observations

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11845

Ranking procedures for arbitrarily restricted observation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11845

The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11845

PCV chemotherapy for recurrent glioblastoma multiforme.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11845

Selection bias in clinical trials of anaplastic glioma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11845

Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11845

World Health Organization classification of tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11845

Malignant glioma: who benefits from adjuvant chemotherapy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11845

PCV chemotherapy for recurrent glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11845

21 January 2018

Identifiers

DOI

10.1002/CNCR.11845

1 reference

14 January 2018

PubMed ID

14669289

1 reference

14 January 2018